Horizon Pharma plc Recognizes Rare Disease Community on the "Rarest Day of the Year"
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil tops $100, yields hit 2023 high; Apple down before Ternus' first launch event as CEO
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Mizuho Securities Remains Bullish on Horizon Pharma (HZNP); Says Subpoena Appears Benign
March 1, 2016 7:01 AM ESTMizuho Securities maintained a Buy rating on Horizon Pharma (NASDAQ: HZNP), and cut the price target to $34.00 (from $36.00), following the company's 4Q earnings report. HZNP reported a strong revenues of $244.5M and EPS of $0.63 vs. consensus estimates of $240.8M and $0.61. Mgmt indicated the... More
Piper Jaffray Remains Bullish on Horizon Pharma (HZNP) Despite Sell-Off; Says Business is Sustainable
February 29, 2016 3:37 PM ESTPiper Jaffray maintained an Overweight rating on Horizon Pharma (NASDAQ: HZNP), and cut the price target to $44.00 (from $46.00), following the company's 4Q earnings report. Horizon reported adjusted EPS of $0.63 on revenues of $245M, coming in ahead of Street estimates. Sales from the primary care business grew 10% sequentially in 4Q15 over 3Q15, with management citing... More
